LianBio — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LianBio filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($110.29M) | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | ($196.30M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($139.60M) | Mar 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($125.35M) | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | ($195.57M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($134.87M) | Mar 31, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $59.76M | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $158.69M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $120.89M | Mar 31, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($99.19M) | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | ($163.95M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($98.14M) | Mar 31, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $1.85M | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $947.0K | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $886.0K | Mar 31, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $319.96M | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $426.34M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $279.29M | Mar 31, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $26.31M | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $39.01M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $27.57M | Mar 31, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $259.87M | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $353.56M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($132.84M) | Mar 31, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($470.53M) | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | ($360.24M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($163.94M) | Mar 31, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $79.22M | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $228.18M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $254.35M | Mar 31, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | (1) | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | (5) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | (11) | Mar 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | (1) | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | (5) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | (11) | Mar 31, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 107.04M | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | 107.28M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 20.48M | Mar 31, 2022 |